EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome

Leonard B Weinstock, Lawrence B Afrin, Angela M Reiersen, Jill Brook, Svetlana Blitshteyn, Gillian Ehrlich, Jill R Schofield, Laurence Kinsella, David Kaufman, Tania Dempsey, Gerhard J Molderings

Brain, Behavior, & Immunity - Health · 2025-10 · 48 · 101048

DOI: 10.1016/j.bbih.2025.101048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, Behavior, & Immunity - Health, 2025-10. Verfasst von Leonard B Weinstock und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Gastrointestinal Alliance, 11525 Olde Cabin Road, St. Louis, MO, 63141, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuropsychiatric disorders have been observed in mast cell activation syndrome (MCAS). MCAS is a common, yet rarely diagnosed, inflammatory, and immunologic disease characterized by mast cell dysregulation.

Methods

Questionnaires from 553 MCAS and 558 control subjects determined the prevalence and odds ratio of neurologic disorders (fatigue, cognitive dysfunction, fainting/near fainting, migraine-like headaches, muscle pain/tenderness/weakness, pain/numbness/tingling in extremities, restless legs syndrome, seizure-like activity, insomnia, sleep attacks, tinnitus, acoustic startle, Tourette's syndrome, resting tremor, and light/sun/pain/odors/scents/noise hypersensitivity) and psychiatric disorders (anxiety, agoraphobia, panic attacks, depression, bipolar depression, mania/hypomania, psychosis/schizophrenia, hallucinations, obsessive compulsive disorder, attention-deficit/hyperactivity disorder, anger management problems, post-traumatic stress disorder, suicidal thoughts, and eating disorders).

Results

Among 19 neurologic disorders, female MCAS patients reported higher rates in all but 1 disorder and male MCAS patients reported higher rates in all but 2 disorders. Among 14 psychiatric disorders, female MCAS patients reported higher rates in all and male MCAS patients reported higher rates in 8 disorders. Many of the disorders with increased prevalences were statistically greater compared to corresponding controls.In self-reported ratings for effects on health status (0 = no benefit, 10 = maximum benefit), mean (SD) response was 6.3 (2.5) for antihistamines, 5.6 (3.2) for low-dose naltrexone, and 5.6 (3.1) for benzodiazepines.

Conclusion

MCAS subjects have significantly elevated odds ratios for many neuropsychiatric disorders and may see improvement of symptoms using MCAS-targeted therapies, suggesting that mast cell dysregulation affects the brain and peripheral nervous systems and contributes to neuropsychiatric symptoms. Certain mast cell mediators, specific genetic predisposition, and life experiences could determine which disorder is apt to develop or worsen.

Schlagwörter

Stichwörter der Autor:innen

MCASMast cell activation syndromeNeurologicPsychiatric

Autor:innen und Institutionen

  • Gastroenterology Department, Gastrointestinal Alliance, 11525 Olde Cabin Road, St. Louis, MO, 63141, USA.
  • AIM Center for Personalized Medicine, Senior Consultant in Hematology/Oncology, Department of Mast Cell Studies, 3010 Westchester Avenue, Suite 404, Armonk, NY, 10577, USA.
  • Washington University in St. Louis School of Medicine, Department of Psychiatry Box 8134, 660 S Euclid Ave, St. Louis MO, 63110, USA.
  • PatientsCount.org, 13285 Roundhill Drive, Truckee, CA, 96161, USA.
  • Clinical Associate Professor of Neurology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY 14203, USA.
  • Neuroveda Health, 1700 Westlake Ave N, Suite 100, Seattle, WA, 98109, USA.

Zitieren

APA

Weinstock, L. B., Afrin, L. B., Reiersen, A. M., Brook, J., Blitshteyn, S., Ehrlich, G., Schofield, J. R., Kinsella, L., Kaufman, D., Dempsey, T., & Molderings, G. J. (2025). Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome. Brain, Behavior, & Immunity - Health, 48, 101048. https://doi.org/10.1016/j.bbih.2025.101048

Vancouver

Weinstock LB, Afrin LB, Reiersen AM, Brook J, Blitshteyn S, Ehrlich G, et al. Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome. Brain, Behavior, & Immunity - Health. 2025;48:101048. doi:10.1016/j.bbih.2025.101048

BibTeX
@article{Weinstock2025,
  author = {Weinstock, Leonard B and Afrin, Lawrence B and Reiersen, Angela M and Brook, Jill and Blitshteyn, Svetlana and Ehrlich, Gillian and Schofield, Jill R and Kinsella, Laurence and Kaufman, David and Dempsey, Tania and Molderings, Gerhard J},
  title = {Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome},
  journal = {Brain, Behavior, & Immunity - Health},
  year = {2025},
  volume = {48},
  pages = {101048},
  doi = {10.1016/j.bbih.2025.101048}
}
Kostenlos starten →